Safety and Pharmacokinetics Study of Multiple Ascending Doses of VV261 Tablets
NCT07710326
·
clinicaltrials.gov ↗
PHASE1
Phase
NOT_YET_RECRUITING
Status
16
Enrollment
INDUSTRY
Sponsor class
Conditions
Healthy Volunteers
Interventions
DRUG:
VV261 600mg TID group
DRUG:
VV261 900mg TID group
Sponsor
Vigonvita Life Sciences